key: cord-1001187-xlbev1po authors: Nusrat, Sanober; Borogovac, Azra; George, James N.; Curtis, Brian R.; Reese, Jessica A. title: Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features date: 2022-02-15 journal: Am J Hematol DOI: 10.1002/ajh.26482 sha: c467145029f57c6611ce014c9fb023397e1617c1 doc_id: 1001187 cord_uid: xlbev1po nan Pembrolizumab (9) Nivolumab/Ipilimumab (6) Ipilimumab (2) Nivolumab/Pembrolizumab (1) Durvalumab (2) a Citations for the reports of these five drugs are in Table S1 . None. Dr. Curtis is a consultant for Argenx, Ionis, and Rallybio pharmaceuticals. The other four authors have no conflicts of interest or financial conflicts with this study. This study involved no human or animal subjects and required no Institutional Review Board approval. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene Drug-induced immune thrombocytopenia Drug-induced thrombocytopenia: a systematic review of published case reports Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy Immune-related adverse events associated with immune checkpoint blockade Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drugdependent antibodies ORCID James N. George https://orcid.org/0000-0002-4243-2691Jessica A. Reese https://orcid.org/0000-0002-6640-6543